Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
Login Archives Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • AI Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    • Postcards
    ×
  • Subscribe
Enter stock ticker or keyword
×
Join 100,000+ Like-Minded Investors Today
Twitter
Tags: Penny stocks
Stocks: APRI, AVEO, DVAX, IMNP, XLK

3 Best Biotech Penny Stocks to Buy with February Catalysts

By William Romov, Associate Editor, Money Morning • February 6, 2018

View Comments

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

Although Wall Street and the mass media are obsessed with the technology sector, the biggest profits are in the biotechnology industry.

Over the last 12 months, the S&P Biotechnology Select Industry Index (SPSIBI) climbed an impressive 41.31%.

Meanwhile, over the same period, the S&P 500 Technology Sector SPDR ETF (NYSE: XLK) has returned 34.28%.

Biotech

That's why today we'll reveal our three best biotech penny stocks to buy.

All three have upcoming February clinical trial results that could send their share prices soaring 300%-plus. One even has profit potential of more than 500%.

If a biotech stock's clinical trial results are positive, or receives a nod of approval from the FDA, then the stock can soar. For example, last year Dynavax Technologies Corp. (Nasdaq: DVAX) shares more than quadrupled between May 31 and Oct. 5, when it climbed 337.6%, from $5.50 to $24.07.

This jump came in July 2017 after the company reported that an FDA advisory committee voted in favor of the company's lead product candidate, Heplisav-B - an experimental hepatitis B vaccine.

While these stocks have huge profit potentials, you must keep in mind that penny stocks are very speculative investments. They often see big pullbacks after making large gains.

That's why Money Morning recommends that no more than 2% of your stock portfolio consist of such risky investments.

But if you're willing to take the risk, some of these stocks could bring you profits of over 300% next year.

FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it's completely free...

Now, the first biotech penny stock has its sights set on treating a large demographic of men over the age of 40 ...

Biotech Penny Stocks to Buy, No. 3: Apricus Biosciences Inc.

California-based Apricus Biosciences Inc. (Nasdaq: APRI) develops treatments in the areas of urology and rheumatology. Its lead product, Vitaros, is a topically applied cream for the treatment of erectile dysfunction (ED).

ED affects 52% of men and 40% of men above the age of 40, according to the Massachusetts Male Aging Study.

Currently trading at $2.35, APRI shares are covered by two firms, with an average price target of $3.50 and a high target of $4.50. Those targets represent upside of 49% and 91.5%, respectively.

Although APRI shares don't currently have 500%-plus potential price target, the fact that ED eventually affects the majority of males in the United States means that this drug will be in high demand if approved.

The company submitted its New Drug Application (NDA) to the FDA back in August, with a PDUFA date of Feb. 17.

A PDUFA date is the FDA's deadline to approve or reject an NDA, typically six months after the NDA.

Up next is a stock whose lead drug candidate is already approved in Europe and another stock with 500%-plus potential ...

Here Are 10 “One-Click” Ways to Earn 10% or Better on Your Money Every Quarter

Appreciation is great, but it’s possible to get even more out of the shares you own. A lot more: you can easily beat inflation and collect regular income to spare. There are no complicated trades to put on, no high-level options clearances necessary. In fact, you can do this with a couple of mouse clicks – passive income redefined. Click here for the report…

Claim My Free Report

Subscribe
Login
Notify of
guest

guest

3 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Benedikte Moore
Benedikte Moore
5 years ago

I would like to sign up for money morning newsletter I'm very interested in Biotech, and can't wait to get started.I do not have much trade or stock experience, but I'm watching beginners webinars. Regards Benedikte Moore

0
Reply
Ray
Ray
5 years ago

As a WW, I am using all the information as therapy & what I receive is very helpful for my recovery & all the information is very good. Thank You.

0
Reply
greg winans
greg winans
5 years ago

sounds good

0
Reply


Latest News

October 2, 2023 • By Shah Gilani

earnings
What to Watch for This Week as Markets Continue to Struggle

September 30, 2023 • By Garrett Baldwin

Other Peoples' Kids, Icebreaker Stocks, and the Comedy of the Fed

September 30, 2023 • By Garrett Baldwin

Here's What Happens When I Ask Hard Questions
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Penny Hawk Midday Momentum
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Quantum Data Profits Flashpoint Trader Darknet Alpha Accelerators Brutus Alerts Resource Traders Alliance L.A.U.N.C.H. Investor Rob Roy Trader Long-Term Equity Profits

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz